Arvinas, Inc. (NASDAQ:ARVN) CEO John G. Houston Sells 31,338 Shares

Arvinas, Inc. (NASDAQ:ARVN) CEO John G. Houston sold 31,338 shares of the firm’s stock in a transaction that occurred on Monday, February 24th. The stock was sold at an average price of $16.72, for a total transaction of $523,971.36. Following the completion of the transaction, the chief executive officer now directly owns 1,157,480 shares in the company, valued at $19,353,065.60. This trade represents a 2.64 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Arvinas Stock Performance

Arvinas stock opened at $17.67 on Wednesday. Arvinas, Inc. has a fifty-two week low of $16.07 and a fifty-two week high of $51.51. The firm has a 50 day moving average price of $18.41 and a 200 day moving average price of $22.80. The company has a market capitalization of $1.21 billion, a PE ratio of -6.38 and a beta of 1.88.

Arvinas (NASDAQ:ARVN) last posted its earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.44. Arvinas had a negative net margin of 75.51% and a negative return on equity of 33.75%. During the same period in the prior year, the firm posted ($2.53) earnings per share. As a group, equities research analysts forecast that Arvinas, Inc. will post -3.81 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of research analysts have weighed in on the stock. BTIG Research assumed coverage on shares of Arvinas in a research note on Tuesday, December 10th. They issued a “buy” rating and a $69.00 target price on the stock. BMO Capital Markets reissued an “outperform” rating and issued a $82.00 target price (down from $88.00) on shares of Arvinas in a research note on Wednesday, February 12th. HC Wainwright reissued a “buy” rating and issued a $87.00 target price on shares of Arvinas in a research note on Wednesday, December 11th. Barclays decreased their target price on shares of Arvinas from $48.00 to $32.00 and set an “overweight” rating on the stock in a research note on Monday, February 3rd. Finally, Stephens initiated coverage on shares of Arvinas in a research note on Monday, November 18th. They issued an “overweight” rating and a $55.00 target price on the stock. Twelve investment analysts have rated the stock with a buy rating, According to MarketBeat, the stock currently has an average rating of “Buy” and a consensus target price of $60.00.

Hedge Funds Weigh In On Arvinas

Institutional investors have recently modified their holdings of the business. GF Fund Management CO. LTD. acquired a new position in shares of Arvinas in the fourth quarter worth $28,000. Mirae Asset Global Investments Co. Ltd. grew its stake in shares of Arvinas by 21.5% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock worth $61,000 after acquiring an additional 440 shares in the last quarter. KBC Group NV grew its stake in shares of Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after acquiring an additional 1,255 shares in the last quarter. Quantbot Technologies LP grew its stake in shares of Arvinas by 147.3% in the third quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock worth $108,000 after acquiring an additional 2,601 shares in the last quarter. Finally, KLP Kapitalforvaltning AS acquired a new position in shares of Arvinas in the fourth quarter worth $171,000. Institutional investors and hedge funds own 95.19% of the company’s stock.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.